SUBSTITUEREDE 2-(BETA-NAPHTHYLOXY)-ETHYLPYRAZOLONER FREMGANGSMADE TIL FREMSTILLING DERAF OG DERES ANVENDELSE SOM LEGEMIDDEL
Pyrazolones of formula (I), including the tautomers are novel cpds. (where R1 = H, CF3 or an opt. substd. alkyl, aryl, aralkyl or heteroaryl group and R2 = unsubstd. naphthyl where R1 = H, CF3, >4C alkyl, heteroaryl or substd. aryl or aralkyl otherwise R2 = naphthyl substd. by 1-3 substituents in...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | dan |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SEUTER F MENG K A MOELLER E HORSTMANN H |
| description | Pyrazolones of formula (I), including the tautomers are novel cpds. (where R1 = H, CF3 or an opt. substd. alkyl, aryl, aralkyl or heteroaryl group and R2 = unsubstd. naphthyl where R1 = H, CF3, >4C alkyl, heteroaryl or substd. aryl or aralkyl otherwise R2 = naphthyl substd. by 1-3 substituents independently chosen from halo, CF3, alkyl, alkenyl, alkoxy, alkylamino, cyano, CF3O, nitro, hydroxy, -SOn- alkyl or SOnCF3 ( n = 0-2), two of the substituents may be joined to form a 5-7 membered, opt. unsaturated, opt. branched isocyclic or heterocyclic ring which may contain 1 or 2 atoms of O or S or R2 = biphenylyl. Cpds. may be administered orally or parenterally for therapeutic or prophylactic treatment of thrombo-embolic disorders, blood clots, etc. Pred. daily doses are 0.1-10 mg/kg parenterally or 0.5-100 mg/kg orally. A typical product is (I) where R2 = beta-naphthyl and R1 = 2-methoxy-isobutyl prepd. from 2-(beta-napthyloxylethyl hydrazine and ethyl (beta, beta-dimethyl-beta-methoxy-propionyl) acetate. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_DK546276A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>DK546276A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_DK546276A3</originalsourceid><addsrcrecordid>eNqFjD0PgjAURVkcjPoXTEcduqDi_LCP0tgP0hZjXQgxdTJKgpt_XiTuTvfk5N47Td6uzp0XvkaLDElKVzl6oBqq0pdBmnNYU_xSFSxcjDQaLSksKg6aOwXDxgs5muFGSqE5YWihIGYEdAT0CTVD6ZA4o4hEjkqwQcyTya2993Hxy1myLNAfShq7ZxP7rr3GR3w17LjbZuk-g83fwgdEdjoK</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>SUBSTITUEREDE 2-(BETA-NAPHTHYLOXY)-ETHYLPYRAZOLONER FREMGANGSMADE TIL FREMSTILLING DERAF OG DERES ANVENDELSE SOM LEGEMIDDEL</title><source>esp@cenet</source><creator>SEUTER F ; MENG K A ; MOELLER E ; HORSTMANN H</creator><creatorcontrib>SEUTER F ; MENG K A ; MOELLER E ; HORSTMANN H</creatorcontrib><description>Pyrazolones of formula (I), including the tautomers are novel cpds. (where R1 = H, CF3 or an opt. substd. alkyl, aryl, aralkyl or heteroaryl group and R2 = unsubstd. naphthyl where R1 = H, CF3, >4C alkyl, heteroaryl or substd. aryl or aralkyl otherwise R2 = naphthyl substd. by 1-3 substituents independently chosen from halo, CF3, alkyl, alkenyl, alkoxy, alkylamino, cyano, CF3O, nitro, hydroxy, -SOn- alkyl or SOnCF3 ( n = 0-2), two of the substituents may be joined to form a 5-7 membered, opt. unsaturated, opt. branched isocyclic or heterocyclic ring which may contain 1 or 2 atoms of O or S or R2 = biphenylyl. Cpds. may be administered orally or parenterally for therapeutic or prophylactic treatment of thrombo-embolic disorders, blood clots, etc. Pred. daily doses are 0.1-10 mg/kg parenterally or 0.5-100 mg/kg orally. A typical product is (I) where R2 = beta-naphthyl and R1 = 2-methoxy-isobutyl prepd. from 2-(beta-napthyloxylethyl hydrazine and ethyl (beta, beta-dimethyl-beta-methoxy-propionyl) acetate.</description><edition>2</edition><language>dan</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>1977</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19770606&DB=EPODOC&CC=DK&NR=546276A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19770606&DB=EPODOC&CC=DK&NR=546276A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SEUTER F</creatorcontrib><creatorcontrib>MENG K A</creatorcontrib><creatorcontrib>MOELLER E</creatorcontrib><creatorcontrib>HORSTMANN H</creatorcontrib><title>SUBSTITUEREDE 2-(BETA-NAPHTHYLOXY)-ETHYLPYRAZOLONER FREMGANGSMADE TIL FREMSTILLING DERAF OG DERES ANVENDELSE SOM LEGEMIDDEL</title><description>Pyrazolones of formula (I), including the tautomers are novel cpds. (where R1 = H, CF3 or an opt. substd. alkyl, aryl, aralkyl or heteroaryl group and R2 = unsubstd. naphthyl where R1 = H, CF3, >4C alkyl, heteroaryl or substd. aryl or aralkyl otherwise R2 = naphthyl substd. by 1-3 substituents independently chosen from halo, CF3, alkyl, alkenyl, alkoxy, alkylamino, cyano, CF3O, nitro, hydroxy, -SOn- alkyl or SOnCF3 ( n = 0-2), two of the substituents may be joined to form a 5-7 membered, opt. unsaturated, opt. branched isocyclic or heterocyclic ring which may contain 1 or 2 atoms of O or S or R2 = biphenylyl. Cpds. may be administered orally or parenterally for therapeutic or prophylactic treatment of thrombo-embolic disorders, blood clots, etc. Pred. daily doses are 0.1-10 mg/kg parenterally or 0.5-100 mg/kg orally. A typical product is (I) where R2 = beta-naphthyl and R1 = 2-methoxy-isobutyl prepd. from 2-(beta-napthyloxylethyl hydrazine and ethyl (beta, beta-dimethyl-beta-methoxy-propionyl) acetate.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1977</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFjD0PgjAURVkcjPoXTEcduqDi_LCP0tgP0hZjXQgxdTJKgpt_XiTuTvfk5N47Td6uzp0XvkaLDElKVzl6oBqq0pdBmnNYU_xSFSxcjDQaLSksKg6aOwXDxgs5muFGSqE5YWihIGYEdAT0CTVD6ZA4o4hEjkqwQcyTya2993Hxy1myLNAfShq7ZxP7rr3GR3w17LjbZuk-g83fwgdEdjoK</recordid><startdate>19770606</startdate><enddate>19770606</enddate><creator>SEUTER F</creator><creator>MENG K A</creator><creator>MOELLER E</creator><creator>HORSTMANN H</creator><scope>EVB</scope></search><sort><creationdate>19770606</creationdate><title>SUBSTITUEREDE 2-(BETA-NAPHTHYLOXY)-ETHYLPYRAZOLONER FREMGANGSMADE TIL FREMSTILLING DERAF OG DERES ANVENDELSE SOM LEGEMIDDEL</title><author>SEUTER F ; MENG K A ; MOELLER E ; HORSTMANN H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_DK546276A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>dan</language><creationdate>1977</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SEUTER F</creatorcontrib><creatorcontrib>MENG K A</creatorcontrib><creatorcontrib>MOELLER E</creatorcontrib><creatorcontrib>HORSTMANN H</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SEUTER F</au><au>MENG K A</au><au>MOELLER E</au><au>HORSTMANN H</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>SUBSTITUEREDE 2-(BETA-NAPHTHYLOXY)-ETHYLPYRAZOLONER FREMGANGSMADE TIL FREMSTILLING DERAF OG DERES ANVENDELSE SOM LEGEMIDDEL</title><date>1977-06-06</date><risdate>1977</risdate><abstract>Pyrazolones of formula (I), including the tautomers are novel cpds. (where R1 = H, CF3 or an opt. substd. alkyl, aryl, aralkyl or heteroaryl group and R2 = unsubstd. naphthyl where R1 = H, CF3, >4C alkyl, heteroaryl or substd. aryl or aralkyl otherwise R2 = naphthyl substd. by 1-3 substituents independently chosen from halo, CF3, alkyl, alkenyl, alkoxy, alkylamino, cyano, CF3O, nitro, hydroxy, -SOn- alkyl or SOnCF3 ( n = 0-2), two of the substituents may be joined to form a 5-7 membered, opt. unsaturated, opt. branched isocyclic or heterocyclic ring which may contain 1 or 2 atoms of O or S or R2 = biphenylyl. Cpds. may be administered orally or parenterally for therapeutic or prophylactic treatment of thrombo-embolic disorders, blood clots, etc. Pred. daily doses are 0.1-10 mg/kg parenterally or 0.5-100 mg/kg orally. A typical product is (I) where R2 = beta-naphthyl and R1 = 2-methoxy-isobutyl prepd. from 2-(beta-napthyloxylethyl hydrazine and ethyl (beta, beta-dimethyl-beta-methoxy-propionyl) acetate.</abstract><edition>2</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | dan |
| recordid | cdi_epo_espacenet_DK546276A |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | SUBSTITUEREDE 2-(BETA-NAPHTHYLOXY)-ETHYLPYRAZOLONER FREMGANGSMADE TIL FREMSTILLING DERAF OG DERES ANVENDELSE SOM LEGEMIDDEL |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T10%3A39%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SEUTER%20F&rft.date=1977-06-06&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EDK546276A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |